breast cancer cell

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

RO7567132 (FAP-LTBR) is a novel bispecific antibody that binds and agonizes LTBR bivalently while binds and antagonizes FAP monovalently, thereby limiting the activation of LTBR to the tumor microenvironment, inducing the formation of local tertiary lymphoid structures (TLS), and reducing systemic toxicity. Its mouse alternative can inhibit breast cancer growth, and the effect is better when combined with atezolizumab. In the mouse colorectal cancer model, it can also enhance immune cell infiltration and TLS-like structure formation.

Anbenitamab (KN-026) is a bispecific antibody targeting extracellular domains II and IV of human HER2, blocking both ligand-dependent and independent signaling pathways. Its IgG1 Fc fragment activates FcRγIIIa, triggering strong antibody-dependent cell-mediated cytotoxicity (ADCC) and suppressing tumor cell growth. Anbenitamab shows promise for research in HER2-positive metastatic breast cancer (MBC) [1][2].

Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer.

Praluzatamab is a monoclonal antibody targeting an activated white blood cell adhesion molecule (ALCAM CD116). It is a naked antibody used to synthesize antibody active molecule conjugates (Praluzatamab ravtansine) and can be employed to study breast cancer.

Giloralimab (ABBV-927) is a monoclonal antibody targeting CD40 with potential anticancer activity for the study of triple-negative breast cancer and non-small cell lung cancer.

Ertumaxomab (Anti-Human CD22 Recombinant Antibody) is a bispecific antibody that targets both HER2 neu and CD3. It functions by activating Fcγ type I III receptors, which facilitates the formation of a tri-cell complex involving tumor cells, T cells, and accessory cells. This compound has been utilized in the research of breast cancer [1].

Ladiratuzumab vedotin (SGN-LIV1A) is an ADC (IC 50: 5.6 nM for LIV-1) that targets LIV-1. This compound is composed of a humanized IgG1 monoclonal antibody, linked to MMAE via a protease-cleavable linker. It induces immunogenic cell death (ICD), which triggers an immune response. Ladiratuzumab vedotin is utilized in breast cancer research [1] [2] [3] [4].